D614G Spike Variant Does Not Alter IgG, IgM, or IgA Spike Seroassay Performance

Author:

Klumpp-Thomas, Carleen

Kalish, Heather

Hicks, Jennifer

Mehalko,Jennifer

Drew, Matthew

Memoli, Matthew J

Hall, Matthew D

Esposito,Dom

Sadtler, Kaitlyn
Author Address

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD., Section on Immuno-Engineering, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD., Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD., Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick, MD., LID Clinical Studies Unit, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD.,

Abstract:

Emergence of a new spike protein variant (D614G) with increased infectivity has prompted many to analyze its role in the SARS-CoV-2 pandemic. There is concern regarding whether an individual exposed to one variant of a virus will have cross-reactive memory to the second. Accordingly, we analyzed the serologic reactivity of both variants, and found that antibodies from 88 donors from a high-incidence population reacted toward both the original spike and the D614 spike variant. These data suggest patients who are exposed to either variant have cross-responsive humoral immunity. This represents an important finding both for SARS-CoV-2 disease biology and for therapeutics. Published by Oxford University Press for the Infectious Diseases Society of America 2020. This work is written by (a) US Government employee(s) and is in the public domain in the US.

See More

Author Address